AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10801969 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose zinc supplements
Number of subjects: 0
Study 10801969 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose antioxidants
Number of subjects: 0
Study 10801969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8719121 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BL) at 3000 lux for 6 days after PSD
Number of subjects: 20
Study 8719121 — intervention group
Group type: COMPARATOR
Intervention: Dim light therapy (DL) at 100 lux for 6 days after PSD
Number of subjects: 20
Study 1595849 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg pretreatment
Number of subjects: 40
Study 1595849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6486083 — intervention group
Group type: COMPARATOR
Intervention: Linoleic acid intake of 0% of total energy intake
Number of subjects: 24
Study 6486083 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid intake of 20% of total energy intake
Number of subjects: 24
Study 6486083 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid intake (various levels)
Number of subjects: 24
Study 29445845 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information provided after FC
Number of subjects: 200
Study 29445845 — intervention group
Group type: COMPARATOR
Intervention: Verbal information alone (Control)
Number of subjects: 200
Study 28842084 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Fascial Approach (DFA)
Number of subjects: 46
Study 28842084 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial Fascial Approach (SFA)
Number of subjects: 46
Study 28842084 — intervention group
Group type: COMPARATOR
Intervention: All patients (DFA + SFA)
Number of subjects: 46
Study 25234807 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid therapy (1200 mg per day for 4-6 weeks, then 300-600 mg per day)
Number of subjects: 65
Study 25234807 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard chemotherapy regimen)
Number of subjects: 65
Study 25234807 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid therapy
Number of subjects: 65
Study 23352740 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-voxel pattern analysis (MVPA) fMRI
Number of subjects: 0
Study 21982667 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg/day
Number of subjects: 31
Study 21982667 — intervention group
Group type: COMPARATOR
Intervention: High-dose clopidogrel 150 mg/day
Number of subjects: 31
Study 18495027 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio guided occult lesion localization (ROLL)
Number of subjects: 316
Study 18495027 — intervention group
Group type: COMPARATOR
Intervention: Wire-guided localization (WGL)
Number of subjects: 316
Study 18495027 — intervention group
Group type: EXPERIMENTAL
Intervention: ROLL
Number of subjects: 316
Study 18495027 — intervention group
Group type: COMPARATOR
Intervention: WGL
Number of subjects: 316
Study 17285968 — intervention group
Group type: EXPERIMENTAL
Intervention: Endonasal sinus surgery with frontal sinus opened and drained by two pipes of silicone for 6 months (Group 1)
Number of subjects: 68
Study 17285968 — intervention group
Group type: EXPERIMENTAL
Intervention: Endonasal sinus surgery with frontal sinus opened and drained by two pipes of silicone for 6 months plus injection of beclomethasone (Group 2)
Number of subjects: 68
Study 17285968 — intervention group
Group type: COMPARATOR
Intervention: Only frontal sinus opened (Group 3)
Number of subjects: 68
Study 14603360 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized photo books as part of a comprehensive nursing intervention
Number of subjects: 100
Study 14603360 — intervention group
Group type: COMPARATOR
Intervention: Standard brochures as part of a nurse-teaching intervention
Number of subjects: 100
Study 10970927 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 47
Study 10970927 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 47
Study 8985678 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation applied above the right or left motor cortex at varying time intervals (30 and 110 ms) after a visual stimulus.
Number of subjects: 8
Study 8985678 — intervention group
Group type: COMPARATOR
Intervention: No magnetic stimulation (control condition).
Number of subjects: 8
Study 1457432 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm leukocyte-depleted blood reperfusion (group II; n = 11)
Number of subjects: 20
Study 1457432 — intervention group
Group type: COMPARATOR
Intervention: Warm whole blood reperfusion (group I; n = 9)
Number of subjects: 20
Study 1457432 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 6365157 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 0
Study 6365157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 31165160 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM RCTs
Number of subjects: 764
Study 29635395 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Resolution Therapy (ART); mean number of sessions received: 3.9 ± 1.1.
Number of subjects: 291
Study 25676540 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Δ(9)‐THC (maximum 28 mg/day)
Number of subjects: 498
Study 25676540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study 25676540 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation
Number of subjects: 498
Study 24623718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 448
Study 24623718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study 21917649 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib treatment for 24 months
Number of subjects: 1024
Study 21917649 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H pylori treatment for 7 days
Number of subjects: 1024
Study 21917649 — intervention group
Group type: COMPARATOR
Intervention: H pylori eradication followed by celecoxib
Number of subjects: 1024
Study 19687005 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring with pharmacological treatment for 6 months
Number of subjects: 120
Study 19687005 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring with pharmacological treatment for 6 months (per-protocol analysis)
Number of subjects: 120
Study 19687005 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring group
Number of subjects: 120
Study 19687005 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring group (hospitalized patients)
Number of subjects: 120
Study 19687005 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 17700083 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention program (40 visits over 12 months)
Number of subjects: 59
Study 17700083 — intervention group
Group type: COMPARATOR
Intervention: Control group (center-based program only)
Number of subjects: 59
Study 15286098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran 36 mg twice daily for 8 days
Number of subjects: 16
Study 15286098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15286098 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin 0.5 mg single oral dose on day 4
Number of subjects: 16
Study 11543692 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 18
Study 9701198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg riboflavin daily for 12 weeks
Number of subjects: 92
Study 9701198 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg riboflavin daily for 12 weeks
Number of subjects: 92
Study 9701198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 8611450 — intervention group
Group type: EXPERIMENTAL
Intervention: Campath‐1H (humanized CD52 monoclonal antibody)
Number of subjects: 9
Study 2285631 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl carnitine (PC) 500 mg three times a day for 30 days
Number of subjects: 18
Study 2285631 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) three times a day for 30 days
Number of subjects: 18
Study 6450787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus placebo
Number of subjects: 21
Study 6450787 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus haloperidol
Number of subjects: 21
Study 6450787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus haloperidol
Number of subjects: 21
Study 31466779 — intervention group
Group type: COMPARATOR
Intervention: Control compensable neutral dry (CN; 23.7 ± 0.7 °C; 10.7 ± 0.8%Rh)
Number of subjects: 9
Study 31466779 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensable hot dry (CH; 42.3 ± 0.3 °C; 10.7 ± 1.8%Rh)
Number of subjects: 9
Study 31466779 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncompensable hot humid (UCH; 42.3 ± 0.3 °C; 55.2 ± 7.7%Rh)
Number of subjects: 9
Study 26303352 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB
Number of subjects: 28
Study 26303352 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 23422378 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone or Paliperidone
Number of subjects: 64
Study 23422378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 21273492 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 administration during meal
Number of subjects: 28
Study 21273492 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 administration during OGTT
Number of subjects: 28
Study 21273492 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 administration during hyperglycemic clamps
Number of subjects: 28
Study 21273492 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved glycemic control after 2 months
Number of subjects: 28
Study 21273492 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 administration after improved glycemic control
Number of subjects: 28
Study 21273492 — intervention group
Group type: COMPARATOR
Intervention: Control subjects during meal
Number of subjects: 28
Study 21273492 — intervention group
Group type: COMPARATOR
Intervention: Control subjects during OGTT
Number of subjects: 28
Study 21273492 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients during OGTT
Number of subjects: 28
Study 20112480 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus music therapy (Group Acup. + M)
Number of subjects: 60
Study 20112480 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture (Group Acup.)
Number of subjects: 60
Study 16636212 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate, 600 mg twice per day
Number of subjects: 1460
Study 16636212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1460
Study 15388304 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention manipulation by blurring faces and occluding features (Experiment 1)
Number of subjects: 100
Study 15388304 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlimited time presentation of face pairs (Experiment 2)
Number of subjects: 100
Study 15388304 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of spacing beyond normal limits (Experiment 3)
Number of subjects: 100
Study 11591548 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide, 30 mg
Number of subjects: 710
Study 11591548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study 9334894 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg for > or = 7 weeks
Number of subjects: 8
Study 8228350 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose live oral cholera vaccine strain CVD 103-HgR (5 x 10(9) cfu)
Number of subjects: 177
Study 8228350 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose live oral cholera vaccine strain CVD 103-HgR
Number of subjects: 177
Study 8228350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 8228350 — intervention group
Group type: COMPARATOR
Intervention: Moore swabs in sewers and latrines near households
Number of subjects: 177
Study 31682582 — intervention group
Group type: EXPERIMENTAL
Intervention: Calm Meditation App usage (average 11.49 months, SD 10.49)
Number of subjects: 12151
Study 31682582 — intervention group
Group type: EXPERIMENTAL
Intervention: Calm Meditation App usage duration
Number of subjects: 12151
Study 31682582 — intervention group
Group type: EXPERIMENTAL
Intervention: Calm Meditation App usage frequency
Number of subjects: 12151
Study 31682582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Stories usage
Number of subjects: 12151
Study 29426443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery (phacoemulsification)
Number of subjects: 101
Study 29426443 — intervention group
Group type: COMPARATOR
Intervention: Control (unoperated fellow eyes)
Number of subjects: 101
Study 27849497 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar extensor high‐intensity progressive resistance exercise (HIPRE) training (n = 298)
Number of subjects: 582
Study 27849497 — intervention group
Group type: COMPARATOR
Intervention: Core stabilization exercise training (control) (n = 284)
Number of subjects: 582
Study 24803481 — intervention group
Group type: EXPERIMENTAL
Intervention: Short lifestyle questionnaire (7 pages)
Number of subjects: 31751
Study 24803481 — intervention group
Group type: EXPERIMENTAL
Intervention: Long lifestyle and quality of life questionnaire (10 pages)
Number of subjects: 31751
Study 24803481 — intervention group
Group type: COMPARATOR
Intervention: No questionnaire sent
Number of subjects: 31751
Study 24803481 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall attendance for those born in 1951
Number of subjects: 31751
Study 22925356 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused early childhood obesity prevention intervention
Number of subjects: 542
Study 22925356 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 542
Study 20739728 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) added to usual care
Number of subjects: 41
Study 20739728 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 41
Study 19089259 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush with tongue scraper
Number of subjects: 30
Study 19089259 — intervention group
Group type: COMPARATOR
Intervention: Conventional tongue scraper
Number of subjects: 30
Study 15957680 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 232
Study 15957680 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control
Number of subjects: 232
Study 11837827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertrochanteric external fixator (PF)
Number of subjects: 100
Study 11837827 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw (SHS)
Number of subjects: 100
Study 10421260 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intrahepatic arterial chemotherapy (2-3 courses with a maximum dose of 80 mg of cisplatin and 10 mg of mitomycin C at 1-month intervals)
Number of subjects: 158
Study 10421260 — intervention group
Group type: COMPARATOR
Intervention: Moderate hepatitis (HAI score of 6-9)
Number of subjects: 158
Study 10421260 — intervention group
Group type: COMPARATOR
Intervention: Mild hepatitis (HAI score of 0-5)
Number of subjects: 158
Study 10421260 — intervention group
Group type: COMPARATOR
Intervention: Severe hepatitis (HAI score > or = 10)
Number of subjects: 158
Study 7570405 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose inhaled steroid (400 micrograms beclomethasone dipropionate) + salmeterol (100 micrograms)
Number of subjects: 426
Study 7570405 — intervention group
Group type: COMPARATOR
Intervention: High dose inhaled steroid (1000 micrograms beclomethasone dipropionate)
Number of subjects: 426
Study 1663774 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 62
Study 6182894 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (trimecain) administered intravenously and then intramuscularly for a day
Number of subjects: 316
Study 6182894 — intervention group
Group type: COMPARATOR
Intervention: Control group (155 patients)
Number of subjects: 316
Study 6182894 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine administered intramuscularly for 1.8 years
Number of subjects: 316
Study 31821429 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh red blood cells (stored ≤7 days)
Number of subjects: 1538
Study 31821429 — intervention group
Group type: COMPARATOR
Intervention: Standard-issue red blood cells
Number of subjects: 1538
Study 31821429 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh red blood cells
Number of subjects: 1538
Study 28206682 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost mesh
Number of subjects: 0
Study 28206682 — intervention group
Group type: COMPARATOR
Intervention: Commercial mesh
Number of subjects: 0
Study 25695849 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga/meditation (YM)
Number of subjects: 0
Study 25695849 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 0
Study 23392332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg i.v. (dexamethasone group, n = 20)
Number of subjects: 40
Study 23392332 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group, n = 20)
Number of subjects: 40
Study 21540324 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic benign prostatic hyperplasia (BPH)
Number of subjects: 5068
Study 21540324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5068
Study 19927630 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone plus irbesartan (150 mg/d)
Number of subjects: 63
Study 19927630 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone alone
Number of subjects: 63
Study 17530099 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose E2/NETA (2 mg E2/1 mg NETA)
Number of subjects: 90
Study 17530099 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose E2/NETA (1 mg E2/0.5 mg NETA)
Number of subjects: 90
Study 15167457 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lisinopril (LIS) daily for 4 weeks
Number of subjects: 52
Study 15167457 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide (HCT) daily for 4 weeks
Number of subjects: 52
Study 11483905 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg cisapride
Number of subjects: 20
Study 11483905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9712219 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote interview via telecommunication
Number of subjects: 30
Study 9712219 — intervention group
Group type: COMPARATOR
Intervention: In-person interview
Number of subjects: 30
Study 8067837 — intervention group
Group type: EXPERIMENTAL
Intervention: Low systemic heparinization
Number of subjects: 104
Study 8067837 — intervention group
Group type: COMPARATOR
Intervention: Full systemic heparinization
Number of subjects: 104
Study 2844356 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from care attendants on first day at home for up to 12 hours a week for two weeks
Number of subjects: 903
Study 2844356 — intervention group
Group type: COMPARATOR
Intervention: Standard aftercare
Number of subjects: 903
Study 31952625 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision with Motivational Enhancing Intervention (MEI)
Number of subjects: 220
Study 31952625 — intervention group
Group type: COMPARATOR
Intervention: Supervision as Usual (SAU)
Number of subjects: 220
Study 31397488 — intervention group
Group type: EXPERIMENTAL
Intervention: telbivudine 600 mg/d oral
Number of subjects: 141
Study 31397488 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antiviral drugs)
Number of subjects: 141
Study 28193242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure ulcer prevention care bundle
Number of subjects: 799
Study 26216500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (40-60 mg/day)
Number of subjects: 97
Study 26216500 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular adrenocorticotropic hormone (40-60 IU/every other day)
Number of subjects: 97
Study 23137389 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral altrenogest (0.044 mg/kg; Regumate(®) ) for 11 days
Number of subjects: 41
Study 23137389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal progesterone (1.38 g; CIDR(®) ) for 11 days
Number of subjects: 41
Study 23137389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal progesterone (CIDR(®) ) for 8 days
Number of subjects: 41
Study 23137389 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 41
Study 23137389 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 41
Study 21192268 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 90
Study 21192268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 18975103 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg/day)
Number of subjects: 41
Study 18975103 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 16427318 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCES (Attention-related Cognitive Errors Scale)
Number of subjects: 0
Study 16427318 — intervention group
Group type: EXPERIMENTAL
Intervention: MAAS (Mindful Attention Awareness Scale)
Number of subjects: 0
Study 16427318 — intervention group
Group type: EXPERIMENTAL
Intervention: SART (Sustained Attention to Response Task)
Number of subjects: 0
Study 16427318 — intervention group
Group type: EXPERIMENTAL
Intervention: BPS (Boredom Proneness Scale)
Number of subjects: 0
Study 12544071 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mmol/kg Gd‐BOPTA
Number of subjects: 41
Study 12544071 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mmol/kg Gd‐DTPA
Number of subjects: 41
Study 11032589 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 40 mg/d
Number of subjects: 899
Study 11032589 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/d
Number of subjects: 899
Study 11032589 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 40 mg/d (ER-positive subgroup)
Number of subjects: 899